Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
The first drug with Captisol in the formulation was approved in 2001 in Sweden. Captisol is currently in 15 FDA-approved products and additional approvals are expected in the next 24 months. These products span many types of molecules (neutral, charged, MW [236-808]), many indications (antiviral, oncology, antifungal, antipsychotic,etc.), and many presentations (ready to use parenteral solution, concentrate, lyophilized powder in a vial, oral liquid). With over 20 years of Captisol experience in patients worldwide, Captisol has an excellent performance history. For more information on regulatory information and experience, click here.
